Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

ASH 2014: Expert discussion on the latest in AML

Pembrolizumab may bring hope for patients with Hodgkin lymphoma

Immunology highlights from ASH 2014

Comment: Blinatumomab for acute lymphocytic leukaemia

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma

ASH 2014: Expert discussion on the latest in CLL

Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study

Relapsed multiple myeloma responds to combination therapy with daratumumab

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study